HIGHLIGHTS
- who: Mechanism-related circulating proteins as and colleagues from the Pfizer Oncology, La Jolla, CA, USA have published the article: Mechanism-related circulating proteins as biomarkers for clinical outcome in patients with unresectable hepatocellular carcinoma receiving sunitinib, in the Journal: (JOURNAL)
- what: The authors report a detailed exploratory analysis of the pharmacodynamics and predictive value of these sunitinib targetrelated plasma_proteins. The authors have investigated the plasma pharmacodynamics of a number of sunitinib targetrelated soluble proteins and investigated potential relationships between these proteins and measures of clinical outcome, as part of a phase II study of . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.